Entyvio belongs to a drug class called integrin receptor antagonists. It works by blocking the effects of integrin (a type of protein). The exact mechanism of action of Entyvio isn’t known.

To learn about Entyvio’s mechanism of action (how it works) for these conditions, see this article. The Food and Drug Administration (FDA) approves prescription drugs such as Entyvio to treat ...

But the mechanism of action of a major monoclonal antibody developed ... and it is prescribed under the brand name Entyvio, which was approved by the U.S. Food and Drug Administration a decade ...

As a gut-selective integrin antagonist, ENTYVIO offers a differentiated mechanism of action compared to anti-TNF therapies, which contributes to its positioning as a safer long-term option ...

Morphic Holding is developing innovative oral integrin therapies with lead candidate MORF-057 in phase 2. MORF-057 targets α4β7, a highly validated mechanism of action similar to Entyvio, which ...

With the introduction of a subcutaneous formulation, ENTYVIO has expanded patient convenience and global accessibility. Continued growth is supported by rising IBD prevalence and ongoing ...